SCHEDULE: Access Industries Exits Day One Biopharmaceuticals

Reporting persons have ceased all beneficial ownership in Day One Biopharmaceuticals following the completion of a tender offer.

Summary

• AI Day1 LLC and associated entities have divested their entire stake in Day One Biopharmaceuticals, Inc.
• The divestment occurred via a tender offer by Servier Detroit Inc. at a price of $21.50 per share.
• Pre-funded warrants held by the reporting persons were converted into cash at $21.4999 per warrant.
• The reporting persons no longer hold any beneficial ownership in the issuer as of April 23, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing confirming the completion of a previously announced exit strategy.

Positives

• Successful exit of investment position at a defined cash price of $21.50 per share.
• Full liquidation of holdings confirms the completion of the acquisition process by the purchaser.

Negatives

• The reporting persons no longer maintain any equity interest or influence in the company.

Risks

• None; the reporting persons have fully exited their position.

Future Outlook

The reporting persons have no further interest in the issuer and provide no future outlook as they have fully divested.

Industry Context

StockSavvy.ai notes that this filing marks the final stage of a corporate acquisition, reflecting the ongoing consolidation trend within the biopharmaceutical sector where larger entities acquire specialized firms to bolster their drug pipelines.

Comparison to Industry Standards

• The exit via a cash tender offer is a standard mechanism for private equity and institutional investors to realize gains in biotech M&A transactions.
• The $21.50 per share valuation aligns with typical acquisition premiums observed in mid-cap pharmaceutical buyouts.

Stakeholder Impact

• Shareholders have received cash consideration for their shares as part of the acquisition.
• The reporting persons are no longer stakeholders in the company.

Next Steps

• None; the reporting persons have fully exited the investment.

Key Dates

Keywords

Day One Biopharmaceuticals, Access Industries, Tender Offer, Divestment, Merger, Schedule 13D